Chronic Heart Failure Management: Monitoring Patients and Intercepting Exacerbations.

Autor:	Piccirillo G; Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari, Policlinico Umberto I, 'Sapienza'' University of Rome, 00161 Rome, Italy., Moscucci F; Department of Internal Medicine and Medical Specialties, Policlinico Umberto I, 00161 Rome, Italy., Sciomer S; Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari, Policlinico Umberto I, 'Sapienza'' University of Rome, 00161 Rome, Italy., Magrì D; Dipartimento di Medicina Clinica e Molecolare, S. Andrea Hospital, 'Sapienza'' University of Rome, 00189 Rome, Italy.
Jazyk:	angličtina
Zdroj:	Reviews in cardiovascular medicine [Rev Cardiovasc Med] 2023 Jul 17; Vol. 24 (7), pp. 208. Date of Electronic Publication: 2023 Jul 17 (Print Publication: 2023).
DOI:	10.31083/j.rcm2407208
Abstrakt:	Despite significant progress in the field of therapy and management, chronic heart failure (CHF) still remains one of the most common causes of morbidity and mortality, especially among the elderly in Western countries. In particular, frequent episodes of decompensation and, consequently, repeated hospitalizations represent an unsustainable burden for national health systems and the cause of worsening quality of life. CHF is more prevalent in elderly women, who often have "peculiar" clinical characteristics and a more preserved ejection fraction caused by endothelial dysfunction and micro-vessel damage. At the moment, noninvasive technologies that are able to remotely monitor these patients are not widely available yet, and clinical trials are underway to evaluate invasive remote sensors. Unfortunately, implantable devices for identifying decompensation are not the most practical solution in the majority of of patients with chronic heart failure. In particular, they are hypothesized to have the possibility of monitoring patients by pro-B-type natriuretic peptide, ventricular repolarization variability, and bioimpedance cardiography at the first point of care, but new technology and clinical trials must be planned to address the development and spread of these emergent possibilities. Competing Interests: The authors declare no conflict of interest. Damiano Magrì is serving as Guest Editor of this journal. We declare that Damiano Magrì had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Leonardo De Luca and Sophie Mavrogeni. (Copyright: © 2023 The Author(s). Published by IMR Press.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu